Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome

Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome (also known as STRID syndrome or Muscat syndrome) is an extremely rare genetic neurodevelopmental disorder characterized by the combination of spastic tetraplegia (increased muscle tone and stiffness affecting all four limbs), retinitis pigmentosa (a progressive degeneration of the retina leading to vision loss), and intellectual disability. The condition affects multiple body systems, primarily the central nervous system, the musculoskeletal system, and the eyes. Affected individuals typically present in infancy or early childhood with severe motor impairment due to spastic tetraplegia, which significantly limits voluntary movement and functional independence. The retinitis pigmentosa component leads to progressive visual impairment, often beginning with night blindness and loss of peripheral vision, eventually progressing to more severe visual loss. Intellectual disability ranges from moderate to severe, further impacting the individual's ability to achieve developmental milestones. Additional features may include seizures and microcephaly in some patients. There is currently no cure for this syndrome. Management is supportive and multidisciplinary, involving physical therapy and rehabilitation to address spasticity and motor limitations, ophthalmologic monitoring and low-vision aids for retinitis pigmentosa, antiepileptic medications if seizures are present, and educational and developmental support services tailored to the individual's cognitive abilities. The prognosis depends on the severity of each component of the syndrome.

Common questions about Spastic tetraplegia-retinitis pigmentosa-intellectual disability syndrome